News | August 17, 2025
Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
Annual EBITDA margin expands by 170 basis points
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
The product will be marketed by Dr. Reddy's
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
The samples of both products mentioned in the CDSCO list are spurious and not manufactured by Alkem
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
Subscribe To Our Newsletter & Stay Updated
